

# Fortunato Ciardiello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4009045/publications.pdf>

Version: 2024-02-01

367  
papers

30,961  
citations

7069

78  
h-index

5364

164  
g-index

375  
all docs

375  
docs citations

375  
times ranked

30675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
2	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. <i>Journal of Personalized Medicine</i> , 2022, 12, 128.	1.1	6
3	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.	3.5	7
4	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 813462.	1.3	2
5	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
6	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. <i>Cancer Treatment Reviews</i> , 2022, 105, 102373.	3.4	12
7	Immunotherapy for head and neck cancer: Present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103679.	2.0	45
8	A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study. <i>Cancers</i> , 2022, 14, 142.	1.7	3
9	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 708.	1.0	4
10	Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	2.3	24
11	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. <i>Cancers</i> , 2022, 14, 2102.	1.7	12
12	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167
13	A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2669-2669.	0.8	0
14	Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3636-TPS3636.	0.8	0
15	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 15.	3.5	13
16	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592094941.	1.4	35
17	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	0.8	254
18	Dual inhibition of TGF $\beta$ 2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021, 38, 24.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	0.9	23
20	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. <i>Clinical Epigenetics</i> , 2021, 13, 66.	1.8	36
21	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. <i>Journal of Personalized Medicine</i> , 2021, 11, 206.	1.1	2
22	Cancer Treatmentâ€“Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 45.	1.3	20
23	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1941.	1.7	21
24	Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. <i>Cancers</i> , 2021, 13, 2339.	1.7	4
25	PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3109.	0.8	1
26	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021, 21, 549.	1.1	10
27	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. <i>Cancer Treatment Reviews</i> , 2021, 97, 102172.	3.4	27
28	Epigenetic mechanisms underlying prostate cancer radioresistance. <i>Clinical Epigenetics</i> , 2021, 13, 125.	1.8	17
29	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , 2021, 17, 1977-1985.	1.1	24
30	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	3.4	80
31	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. <i>Biomedicines</i> , 2021, 9, 1045.	1.4	4
32	Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants. <i>Cancers</i> , 2021, 13, 4398.	1.7	14
33	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021, 20, 227-235.	1.0	10
34	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	1.7	6
35	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
36	Baseline IFN- $\gamma$ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17626.	1.6	20

#	ARTICLE	IF	CITATIONS
37	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	1.3	23
38	Towards the era of precision medicine in metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000685.	2.0	0
39	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000753.	2.0	25
40	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	1.3	11
41	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
42	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
43	Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 130.	1.3	4
44	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
45	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
46	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli". <i>ESMO Open</i> , 2020, 5, e000675.	2.0	11
47	Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2814.	1.8	18
48	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. <i>British Journal of Cancer</i> , 2020, 122, 1782-1790.	2.9	11
49	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.	3.4	34
50	Primary cutaneous DLBCL non-GCB type: challenges of a rare case. <i>Open Medicine (Poland)</i> , 2020, 15, 119-125.	0.6	25
51	<p></p>Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 867-876.	1.0	8
52	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 164-177.	0.4	4
53	How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 16, 1-24.	0.3	0
54	Why chemo-free treatment intervals can improve care of patients with metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 16, 3-5.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.	1.7	36
56	Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma. <i>Thoracic Cancer</i> , 2019, 10, 2308-2311.	0.8	3
57	Cancer- and non-cancer related chronic pain: from the physiopathological basics to management. <i>Open Medicine (Poland)</i> , 2019, 14, 761-766.	0.6	28
58	Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. <i>Medical Oncology</i> , 2019, 36, 83.	1.2	5
59	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019, 17, 292.	1.8	49
60	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	13.9	918
61	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. <i>Cancers</i> , 2019, 11, 1430.	1.7	15
62	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 41.	3.5	57
63	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. <i>Cancer Research</i> , 2019, 79, 4315-4323.	0.4	9
64	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , 2019, 11, 859.	1.7	27
65	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 236.	3.5	17
66	Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from <i>Astragalus boeticus</i> L.. <i>Molecules</i> , 2019, 24, 1725.	1.7	15
67	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	3.4	224
68	Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 314-323.	0.6	3
69	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 178.	3.5	28
70	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	5.1	368
71	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 845-855.	1.9	58
72	Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. <i>Scientific Reports</i> , 2019, 9, 4986.	1.6	15

#	ARTICLE	IF	CITATIONS
73	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. <i>Cancers</i> , 2019, 11, 399.	1.7	46
74	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
75	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. <i>ESMO Open</i> , 2019, 4, e000533.	2.0	1
76	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.	2.0	49
77	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000519.	2.0	5
78	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
79	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. <i>ESMO Open</i> , 2019, 4, e000536.	2.0	26
80	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. <i>ESMO Open</i> , 2019, 4, e000551.	2.0	15
81	Use of rituximab in NHL malt type pregnant in I <sup>o</sup> trimester for two times. <i>Open Medicine (Poland)</i> , 2019, 14, 757-760.	0.6	24
82	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	1.3	10
83	Differential diagnosis: retroperitoneal fibrosis and oncological diseases. <i>Open Medicine (Poland)</i> , 2019, 15, 22-26.	0.6	19
84	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	3.4	158
85	Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 638-638.	0.8	4
86	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 688-688.	0.8	14
87	A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS173-TPS173.	0.8	2
88	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS731-TPS731.	0.8	7
89	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	2.0	29
90	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. <i>JAMA Oncology</i> , 2018, 4, e175245.	3.4	98

#	ARTICLE	IF	CITATIONS
91	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2018, 19, 301-314.	1.1	7
92	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018, 13, 810-820.	0.5	29
93	Novel <i>In Vitro</i> Cancer Models for Optimizing Anti-EGFR Therapies. <i>Clinical Cancer Research</i> , 2018, 24, 727-729.	3.2	2
94	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	0.8	42
95	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3595.	1.8	78
96	What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2659.	1.8	41
97	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	1.9	46
98	30 Immunotherapy in advanced NSCLC: from the "tsunami" of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	2.0	10
99	Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives. <i>Frontiers in Endocrinology</i> , 2018, 9, 115.	1.5	26
100	Role and targeting of anaplastic lymphoma kinase in cancer. <i>Molecular Cancer</i> , 2018, 17, 30.	7.9	71
101	Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells. <i>Scientific Reports</i> , 2018, 8, 5309.	1.6	33
102	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	1.8	72
103	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018, 20, 721-733.	2.3	65
104	Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. <i>Oncotarget</i> , 2018, 9, 19273-19282.	0.8	10
105	EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. <i>Gastroenterology</i> , 2017, 153, 178-190.e10.	0.6	72
106	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. <i>Digestive and Liver Disease</i> , 2017, 49, 197-201.	0.4	5
107	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. <i>Cancer Treatment Reviews</i> , 2017, 53, 61-69.	3.4	118
108	The Cancer Moonshot from a European perspective. <i>Lancet Oncology</i> , The, 2017, 18, e626.	5.1	0

#	ARTICLE	IF	CITATIONS
109	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. <i>Medical Oncology</i> , 2017, 34, 186.	1.2	7
110	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000132.	2.0	61
111	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017, 2, e000177.	2.0	27
112	Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7447-7458.	2.9	25
113	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 194.	3.4	555
114	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
115	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , 2017, 8, 82773-82783.	0.8	8
116	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	0.8	24
117	Implication of the Hedgehog pathway in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 4330.	1.4	54
118	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017, 8, 23020-23032.	0.8	33
119	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 57528-57536.	0.8	7
120	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017, 8, 67592-67604.	0.8	15
121	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 68305-68316.	0.8	27
122	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. <i>Oncotarget</i> , 2016, 7, 66595-66605.	0.8	78
123	Metformin increases antitumor activity of MEK inhibitors through G11 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016, 7, 4265-4278.	0.8	58
124	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
125	Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. <i>ESMO Open</i> , 2016, 1, e000114.	2.0	6
126	Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. <i>Oncology Letters</i> , 2016, 12, 4505-4509.	0.8	0



#	ARTICLE	IF	CITATIONS
127	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1153-1169.	0.5	9
128	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465.	1.1	37
129	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
130	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. <i>ESMO Open</i> , 2016, 1, e000060.	2.0	325
131	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. <i>ESMO Open</i> , 2016, 1, e000088.	2.0	85
132	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	1.1	15
133	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , 2016, 21, 292-300.	1.9	40
134	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS774-TPS774.	0.8	18
135	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.	1.4	94
136	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1133-1141.	0.5	212
137	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015, 21, 4153-4164.	3.2	21
138	Reply to S. Debska-Szmich et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3518-3518.	0.8	1
139	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	0.8	361
140	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 692-700.	0.8	686
141	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. <i>Oncology Letters</i> , 2015, 9, 1628-1632.	0.8	25
142	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015, 16, 325-333.	1.1	65
143	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	1.3	47
144	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015, 64, 921-928.	6.1	22

#	ARTICLE	IF	CITATIONS
145	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. <i>Clinical Cancer Research</i> , 2015, 21, 2975-2983.	3.2	63
146	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4686-4697.	3.2	103
147	Optimizing Anti-EGFR Therapy in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5415-5416.	3.2	9
148	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	2.9	226
149	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 217-224.	1.0	1
150	A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. <i>Clinical Lung Cancer</i> , 2015, 16, 57-59.	1.1	16
151	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	0.8	27
152	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3634-TPS3634.	0.8	2
153	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 565-565.	0.8	2
154	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS789-TPS789.	0.8	2
155	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015, 6, 23281-23296.	0.8	55
156	Treatment of esophagogastric junction carcinoma: An unsolved debate. <i>World Journal of Gastroenterology</i> , 2015, 21, 4427-4431.	1.4	4
157	Regional variation in physicians' awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. <i>Journal of Clinical Oncology</i> , 2015, 33, 574-574.	0.8	0
158	The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15224-e15224.	0.8	0
159	Role of HGF/MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. <i>Biomedicines</i> , 2014, 2, 345-358.	1.4	30
160	Treatment of gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 1635.	1.4	508
161	Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors. <i>Lung Cancer Management</i> , 2014, 3, 77-84.	1.5	0
162	ALK inhibitors and advanced non-small cell lung cancer (Review). <i>International Journal of Oncology</i> , 2014, 45, 499-508.	1.4	37

#	ARTICLE	IF	CITATIONS
163	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 733-737.	0.5	28
164	Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. <i>Endocrine</i> , 2014, 46, 39-42.	1.1	22
165	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 166-170.	1.1	25
166	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 279-287.	1.0	0
167	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. <i>Clinical Colorectal Cancer</i> , 2014, 13, 145-155.	1.0	15
168	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 809-821.	1.9	29
169	Emerging drugs targeting PD-1 and PD-L1: reality or hope?. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 557-569.	1.0	10
170	Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014, 15, 173-181.	1.1	56
171	ALK inhibitors in the treatment of advanced NSCLC. <i>Cancer Treatment Reviews</i> , 2014, 40, 300-306.	3.4	152
172	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. <i>Clinical Cancer Research</i> , 2014, 20, 3775-3786.	3.2	89
173	Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 299-308.	0.8	0
174	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3505-3505.	0.8	41
175	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3506.	0.8	40
176	Clinical management of advanced gastric cancer: The role of new molecular drugs. <i>World Journal of Gastroenterology</i> , 2014, 20, 14537.	1.4	41
177	Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?. <i>Journal of Thoracic Disease</i> , 2014, 6, 578-80.	0.6	15
178	Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4080-4080.	0.8	0
179	Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15257-e15257.	0.8	0
180	Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e14613-e14613.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. Journal of Clinical Oncology, 2014, 32, e15256-e15256.	0.8	0
182	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncology, 2013, 8, 55-67.	1.7	72
183	Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opinion on Emerging Drugs, 2013, 18, 97-107.	1.0	11
184	Metformin in lung cancer: rationale for a combination therapy. Expert Opinion on Investigational Drugs, 2013, 22, 1401-1409.	1.9	23
185	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. European Journal of Cancer, 2013, 49, 1161-1168.	1.3	151
186	Delivery optimization of erlotinib according to toxicity: May clinical practice go beyond research?. Lung Cancer, 2013, 80, 352-353.	0.9	0
187	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opinion on Biological Therapy, 2013, 13, 241-255.	1.4	50
188	Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 27-37.	1.4	70
189	Emerging VEGF-receptor inhibitors for colorectal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 25-37.	1.0	26
190	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. International Journal of Cancer, 2013, 133, 2089-2101.	2.3	81
191	Improving outcomes in colorectal cancer: Where do we go from here?. European Journal of Cancer, 2013, 49, 2476-2485.	1.3	43
192	Increased TGF- $\beta$ as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research, 2013, 19, 6751-6765.	3.2	130
193	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. Therapeutic Advances in Medical Oncology, 2013, 5, 51-72.	1.4	11
194	Reply to V. Lorusso et al. Journal of Clinical Oncology, 2013, 31, 289-290.	0.8	0
195	The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biology and Therapy, 2013, 14, 1143-1146.	1.5	51
196	Medical treatment of small cell lung cancer: state of the art and new development. Expert Opinion on Pharmacotherapy, 2013, 14, 2019-2031.	0.9	24
197	Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research, 2013, 19, 3508-3519.	3.2	106
198	Preoperative treatment of locally advanced esophageal carcinoma. International Journal of Oncology, 2013, 43, 1745-1753.	1.4	8

#	ARTICLE	IF	CITATIONS
199	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. <i>Oncology Reports</i> , 2013, 30, 2992-2998.	1.2	11
200	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013, 5, 49.	0.9	5
201	Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell'Alta Italia Meridionale (GOIM).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14565-e14565.	0.8	3
202	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3648-TPS3648.	0.8	7
203	Inpatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2861-2868.	0.8	117
204	The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 6155-6168.	0.9	12
205	Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2012, 18, 1051-1062.	3.2	41
206	Is there a role for maintenance therapy in advanced non-small-cell lung cancer?. <i>Clinical Practice (London, England)</i> , 2012, 9, 77-86.	0.1	0
207	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	0.5	23
208	Current status of targeted therapies in advanced gastric cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S29-S34.	1.5	35
209	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 949-959.	1.9	21
210	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. <i>European Journal of Cancer</i> , 2012, 48, 1466-1475.	1.3	506
211	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	0.8	229
212	Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Lung Cancer</i> , 2012, 76, 269-279.	0.9	24
213	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 2011-2019.	0.8	1,713
214	Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. <i>Lung Cancer</i> , 2011, 74, 544-548.	0.9	1
215	HER2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2011, 1, 472-474.	7.7	30
216	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2011, 12, 594-603.	5.1	522

#	ARTICLE	IF	CITATIONS
217	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 1313-1328.	3.9	141
218	Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2011, 6, e28841.	1.1	40
219	EGFR-targeted therapy. <i>Experimental Cell Research</i> , 2011, 317, 2765-2771.	1.2	94
220	Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. <i>Targeted Oncology</i> , 2011, 6, 133-145.	1.7	46
221	Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. <i>BMC Cancer</i> , 2011, 11, 126.	1.1	22
222	Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2011, 12, 420-424.	0.5	42
223	Reply to M.J. Rother. <i>Journal of Clinical Oncology</i> , 2011, 29, 4207-4208.	0.8	0
224	KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. <i>PLoS ONE</i> , 2011, 6, e29146.	1.1	30
225	Trastuzumab Resistance in Breast Cancer. , 2011, , 51-60.		0
226	The search for optimal response prediction in cancer leads to a personalized approach. <i>Targeted Oncology</i> , 2010, 5, 3-4.	1.7	1
227	Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer. <i>Archives of Surgery</i> , 2010, 145, 233.	2.3	17
228	Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 573-573.	3.0	4
229	Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. <i>Cancer Investigation</i> , 2010, 28, 820-827.	0.6	18
230	Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2010, 16, 4990-5001.	3.2	79
231	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. <i>Endocrine-Related Cancer</i> , 2010, 18, 1-11.	1.6	58
232	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010, 67, 86-92.	0.9	23
233	Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1181-1189.	0.8	113
234	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , The, 2010, 11, 753-762.	5.1	1,915

#	ARTICLE	IF	CITATIONS
235	Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. <i>Pharmacogenomics</i> , 2010, 11, 1169-1179.	0.6	41
236	Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2546-2558.	1.9	40
237	Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?. <i>Oncologist</i> , 2009, 14, 137-147.	1.9	48
238	Perspectives in Adjuvant Therapy of Gastric Cancer. <i>Oncology</i> , 2009, 77, 38-42.	0.9	17
239	Novel investigational drugs for gastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 945-955.	1.9	17
240	Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 5-13.	1.4	4
241	Resistance mechanisms of tumour cells to EGFR inhibitors. <i>Clinical and Translational Oncology</i> , 2009, 11, 270-275.	1.2	19
242	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. <i>Targeted Oncology</i> , 2009, 4, 311-322.	1.7	3
243	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 519-527.	12.5	391
244	Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. <i>Oncology Reports</i> , 2009, 21, 1023-8.	1.2	48
245	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008, 216, 698-707.	2.0	33
246	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 200-211.	2.0	56
247	An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial. <i>Clinical Lung Cancer</i> , 2008, 9, 235-238.	1.1	32
248	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. <i>Expert Review of Respiratory Medicine</i> , 2008, 2, 167-178.	1.0	56
249	EGFR Antagonists in Cancer Treatment. <i>New England Journal of Medicine</i> , 2008, 358, 1160-1174.	13.9	1,869
250	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 521-530.	4.3	107
251	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C $\delta$ inhibitor, in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1698-1707.	1.9	27
252	The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer. <i>Current Genomics</i> , 2008, 9, 252-262.	0.7	20

#	ARTICLE	IF	CITATIONS
253	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-epidermal Growth Factor Receptor Drugs in Human Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5069-5080.	3.2	139
254	Second-Line Treatment of Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 430-440.	0.5	58
255	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. <i>Current Signal Transduction Therapy</i> , 2008, 3, 234-243.	0.3	0
256	Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non-small Cell Lung Cancer Cells to Treatment with Gefitinib. <i>Clinical Cancer Research</i> , 2007, 13, 2795-2803.	3.2	248
257	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12468-12473.	3.3	63
258	Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5225-5232.	0.8	306
259	Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. <i>Oncologist</i> , 2007, 12, 840-849.	1.9	100
260	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 335-348.	2.5	5
261	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3091-3100.	1.9	10
262	Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model. <i>Clinical Cancer Research</i> , 2007, 13, 6450-6458.	3.2	37
263	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 236-241.	0.2	0
264	Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 242-248.	0.2	0
265	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 117-126.	0.2	0
266	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 276-283.	0.2	0
267	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 226-235.	0.2	0
268	Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 223-225.	0.2	0
269	Combination of Standard Chemotherapy and Targeted Agents. <i>Journal of Thoracic Oncology</i> , 2007, 2, S19-S23.	0.5	2
270	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. <i>Current Opinion in Oncology</i> , 2007, 19, 98-102.	1.1	20



#	ARTICLE	IF	CITATIONS
271	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007, 10, 81-100.	6.5	74
272	Rational bases for the development of EGFR inhibitors for cancer treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1416-1431.	1.2	115
273	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridizationâ€“Positive/Phospho-Aktâ€“Positive or Never Smoker Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The ONCOBELL Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 2248-2255.	0.8	218
274	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , The, 2007, 8, 500-512.	5.1	89
275	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. <i>World Journal of Surgical Oncology</i> , 2007, 5, 42.	0.8	11
276	A Randomized Phase II Study of Sorafenib/Gemcitabine or Sorafenib/Erlotinib for Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients or Patients with a Performance Status of 2: Treatment Rationale and Protocol Dynamics. <i>Clinical Lung Cancer</i> , 2007, 8, 396-398.	1.1	24
277	Chronic inflammation and oxidative stress in human carcinogenesis. <i>International Journal of Cancer</i> , 2007, 121, 2381-2386.	2.3	809
278	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <i>Differentiation</i> , 2007, 75, 788-799.	1.0	72
279	A Randomized Phase II Study of Pemetrexed or RAD001 as Second-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients: Treatment Rationale and Protocol Dynamics. <i>Clinical Lung Cancer</i> , 2007, 8, 568-571.	1.1	18
280	Mechanisms of resistance to EGFR inhibitors. <i>Targeted Oncology</i> , 2007, 2, 31-37.	1.7	10
281	Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. <i>Targeted Oncology</i> , 2007, 2, 253-257.	1.7	0
282	Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. <i>Oncologist</i> , 2006, 11, 274-284.	1.9	86
283	Key cancer cell signal transduction pathways as therapeutic targets. <i>European Journal of Cancer</i> , 2006, 42, 290-294.	1.3	131
284	Antiangiogenic drugs in non-small cell lung cancer treatment. <i>Current Opinion in Oncology</i> , 2006, 18, 151-155.	1.1	17
285	Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 85-89.	0.6	2
286	ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 33-37.	0.4	30
287	Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery. <i>Annals of Surgical Oncology</i> , 2006, 13, 823-835.	0.7	104
288	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. <i>Targeted Oncology</i> , 2006, 1, 123-129.	1.7	4

#	ARTICLE	IF	CITATIONS
289	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Journal of Cellular Physiology</i> , 2006, 208, 344-353.	2.0	59
290	p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. <i>Journal of Surgical Oncology</i> , 2006, 93, 241-252.	0.8	35
291	Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2006, 12, 577-583.	3.2	86
292	Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1883-1894.	1.9	39
293	Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7099-7107.	3.2	52
294	Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2005, 205, 355-363.	2.0	28
295	Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. <i>Journal of Pathology</i> , 2005, 207, 277-284.	2.1	42
296	Chemosensitization by Antisense Oligonucleotides Targeting MDM2. <i>Current Cancer Drug Targets</i> , 2005, 5, 51-56.	0.8	36
297	A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4741-4748.	3.2	312
298	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 1051-1058.	1.6	31
299	Epidermal growth factor receptor inhibitors in cancer treatment. <i>Future Oncology</i> , 2005, 1, 221-234.	1.1	58
300	Cetuximab in the treatment of colorectal cancer. <i>Future Oncology</i> , 2005, 1, 173-181.	1.1	17
301	Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. <i>Endocrine-Related Cancer</i> , 2005, 12, S159-S171.	1.6	82
302	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 5639-5644.	3.2	83
303	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. , 2005, 63, 93-115.		10
304	The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. <i>Clinical Cancer Research</i> , 2005, 11, 795-805.	3.2	171
305	Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. <i>Clinical Cancer Research</i> , 2005, 11, 1268-76.	3.2	27
306	Angiogenesis: A Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2004, 10, 11-26.	0.9	72

#	ARTICLE	IF	CITATIONS
307	Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy. <i>Clinical Cancer Research</i> , 2004, 10, 784-793.	3.2	337
308	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 3490-3499.	3.2	103
309	Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4858-4864.	3.2	48
310	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. <i>Cancer</i> , 2004, 100, 270-278.	2.0	100
311	Mini Review. <i>Growth Factors</i> , 2004, 22, 133-139.	0.5	39
312	The role of EGFR inhibitors in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 130-135.	1.1	91
313	Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 977-83.	1.9	27
314	Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy. <i>Annals of the New York Academy of Sciences</i> , 2003, 1002, 236-243.	1.8	22
315	Antisense strategies targeting protein kinase C: preclinical and clinical development. <i>Seminars in Oncology</i> , 2003, 30, 26-31.	0.8	35
316	Involvement of Growth Factor Receptors of the Epidermal Growth Factor Receptor Family in Prostate Cancer Development and Progression to Androgen Independence. <i>Clinical Prostate Cancer</i> , 2003, 2, 50-57.	2.1	55
317	Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. <i>Lung Cancer</i> , 2003, 41, 15-22.	0.9	8
318	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 501-514.	1.0	27
319	Cripto., 2003, , 330-334.		0
320	Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. <i>Clinical Cancer Research</i> , 2003, 9, 866-71.	3.2	47
321	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. <i>Clinical Cancer Research</i> , 2003, 9, 1546-56.	3.2	263
322	Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. <i>Clinical Cancer Research</i> , 2003, 9, 1566-72.	3.2	104
323	<i>Helicobacter pylori</i> VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. <i>Clinical Cancer Research</i> , 2003, 9, 2015-21.	3.2	61
324	Anti-epidermal growth factor receptor drugs in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 755-768.	1.9	86

#	ARTICLE	IF	CITATIONS
325	Zd1839 (Iressa <sup>®</sup> ): Preclinical Studies and Pharmacology. <i>Tumori</i> , 2002, 88, S155-S157.	0.6	4
326	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. <i>International Journal of Cancer</i> , 2002, 98, 463-469.	2.3	87
327	Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy. <i>Annals of the New York Academy of Sciences</i> , 2002, 968, 139-147.	1.8	93
328	Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). <i>Clinical Cancer Research</i> , 2002, 8, 3250-8.	3.2	195
329	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. <i>Cancer Research</i> , 2002, 62, 7284-90.	0.4	463
330	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. <i>International Journal of Cancer</i> , 2001, 93, 172-178.	2.3	87
331	Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. , 2000, 85, 710-715.		38
332	A novelMDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. <i>International Journal of Cancer</i> , 2000, 88, 804-809.	2.3	68
333	Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. <i>Oncogene</i> , 2000, 19, 5863-5871.	2.6	88
334	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents. <i>Drugs</i> , 2000, 60, 25-32.	4.9	153
335	8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. <i>Journal of the American College of Cardiology</i> , 2000, 36, 288-293.	1.2	69
336	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. , 1999, 80, 589-594.		39
337	Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 57-62.	1.1	6
338	Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1087-1998.	3.0	72
339	Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 3330-3335.	1.6	88
340	Expression of Wnt5a Is Downregulated by Extracellular Matrix and Mutated c-Ha-ras in the Human Mammary Epithelial Cell Line MCF-10A. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 911-917.	1.0	27
341	The R11± subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor. <i>Oncogene</i> , 1997, 14, 923-928.	2.6	94
342	EGF-related peptides in the pathophysiology of the mammary gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1997, 2, 143-151.	1.0	49

#	ARTICLE	IF	CITATIONS
343	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. , 1997, 73, 277-282.		35
344	Differential immunohistochemical detection of transforming growth factor $\beta$ , amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95
345	Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. , 1996, 66, 538-543.		22
346	NM23 gene expression correlates with cell growth rate and S-phase. International Journal of Cancer, 1995, 60, 837-842.	2.3	66
347	Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. International Journal of Cancer, 1995, 62, 762-766.	2.3	31
348	Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Research and Treatment, 1995, 35, 293-297.	1.1	81
349	The role of amphiregulin in breast cancer. Breast Cancer Research and Treatment, 1995, 33, 103-114.	1.1	62
350	Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 1995, 19, 183-232.	2.0	2,457
351	Flow-cytometric detection of the R1 $\beta$ subunit of type I cAMP-dependent protein kinase in human cells. Cytometry, 1994, 15, 73-79.	1.8	15
352	Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor $\beta$ 1 (TGF- $\beta$ 1): Lack of growth-inhibitory effect on cells expressing the simian virus 40 large-t antigen. International Journal of Cancer, 1994, 56, 736-742.	2.3	25
353	Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbB-2 oncogenes. International Journal of Cancer, 1994, 59, 208-211.	2.3	20
354	Down-regulation of R1 $\beta$ subunit of camp-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-ha-ras and c-erbB-2 proto-oncogenes. International Journal of Cancer, 1993, 53, 438-443.	2.3	46
355	Infection with a transforming growth factor $\beta$ anti-sense retroviral expression vector reduces their vitro growth and transformation of a human colon cancer cell line. International Journal of Cancer, 1993, 54, 952-958.	2.3	31
356	Reduction of R1 $\beta$ Subunit of cAMP-dependent Protein Kinase Expression Induces Growth Inhibition of Human Mammary Epithelial Cells Transformed by TGF- $\beta$ , c-Ha-ras, and c-erbB-2 Genes. Annals of the New York Academy of Sciences, 1993, 698, 102-107.	1.8	4
357	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor- $\beta$ genes on in vitro transformation of human mammary epithelial cells. Molecular Carcinogenesis, 1992, 6, 43-52.	1.3	65
358	Regulation by Estrogen through the 5' Flanking Region of the Transforming Growth Factor $\beta$ Gene. Molecular Endocrinology, 1991, 5, 1955-1963.	3.7	77
359	The role of ras gene expression and transforming growth factor $\beta$ production in the etiology and progression of rodent and human breast cancer. Cancer Treatment and Research, 1991, 53, 107-157.	0.2	8
360	Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an Estrogen-independent phenotype. International Journal of Cancer, 1990, 46, 712-718.	2.3	33

#	ARTICLE	IF	CITATIONS
361	Differential growth factor expression in transformed mouse NIH-3T3 cells. <i>Journal of Cellular Biochemistry</i> , 1990, 42, 45-57.	1.2	23
362	Stromal influences on transformation of human mammary epithelial cells overexpressing c-myc and SV40T. <i>Journal of Cellular Physiology</i> , 1990, 145, 207-216.	2.0	53
363	Transforming growth factor- $\beta$ messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. <i>Developmental Biology</i> , 1990, 140, 123-131.	0.9	78
364	Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA. <i>Molecular Carcinogenesis</i> , 1989, 2, 1-11.	1.3	135
365	Site-selective 8-chloroadenosine 3',5'-cyclic monophosphate inhibits transformation and transforming growth factor $\beta$ production in Ki-ras-transformed rat fibroblasts. <i>FEBS Letters</i> , 1989, 242, 363-367.	1.3	45
366	Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor- $\beta$ production. <i>FEBS Letters</i> , 1989, 250, 474-478.	1.3	18
367	Growth of cells on a perfluorocarbon-medium interphase: A quantitative assay for anchorage-independent cell growth. <i>In Vitro Cellular &amp; Developmental Biology</i> , 1988, 24, 71-78.	1.0	19